Amgen Reports Phase 2 Data for Adagrasib in Lupus nephritis

Amgen today announced Phase 2 results for Adagrasib in patients with Lupus nephritis. The study demonstrated that Adagrasib reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Lupus nephritis and support the continued development of Adagrasib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Adagrasib was consistent with previous observations, with no new safety signals identified.